Veradermics, Inc Net Fee Amt
Veradermics, Inc (MANE) had Net Fee Amt of $234.33 thousand as of 2026-08-07, per its S-1 filed 2026-08-07.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-08-07
- 2026-08-07: Net Fee Amt $234.33K.
- 2026-04-29: Net Fee Amt $7.84K.
- 2026-04-27: Net Fee Amt $39.21K.
| Period end | Net Fee Amt |
|---|---|
| 2026-08-07 | $234.33K S-1 · filed 2026-08-07 |
| 2026-04-29 | $7.84K S-1MEF · filed 2026-04-29 |
| 2026-04-27 | $39.21K S-1 · filed 2026-04-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |